InSysBio announces its participation in BioTechX Europe 2025 on 6–8 October 2025 at Messe Basel, Switzerland. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, is going to present InSysBio's modeling services for drug research & development at the Booth S62. Moreover, Oleg will take part in the roundtable discussion "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges".
Check out our Booth S62 at BioTechX Europe 2025!
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | October 2016 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
1.
22 Oct 2016 20:38
Institute for Systems Biology Moscow to Present Research Results in HCV therapeutic area at ACoP7 Conference
Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
